Send comments and feedback

In use since the 1970s, valproate is highly effective for genetic generalized epilepsies and some forms of pediatric epilepsy. The medication also is associated with a 10% risk of birth defects in children exposed to it in utero, as well as a 30% to 40% risk of neurodevelopmental issues, including autism. Sharp Waves spoke with Dr. Tony Marson about the reproductive risks for women and men taking valproate, discussing UK policies meant to ensure appropriate prescription of valproate and communication about its risks. The recent policy regarding men who take valproate, and the evidence used to support that policy, is discussed near the end of the episode.

Since the episode was recorded, the UK has changed its policy regarding men taking valproate; see this link for more information: February 2025 update on valproate policy in the UK

UK Drug Safety Update page - June 2025

February 2025 update on valproate policy in the UK

Regulatory safety and educational materials on valproate - for health care professionals and patients

Public assessment report: Managing reproductive risks in males under 55 taking valproate

Sharp Waves episodes are meant for informational purposes only, and not as clinical or medical advice.

Let us know how we're doing: [email protected].

The International League Against Epilepsy is the world's preeminent association of health professionals and scientists, working toward a world where no person's life is limited by epilepsy. Visit us on Facebook, Instagram, and LinkedIn.